$BSX (Boston Scientific Corporation)

$BSX {{ '2015-10-28T12:30:38+0000' | timeago}} • Webcast

$BSX recently got US approval of SYNERGY Bioabsorbable Polymer Drug-Eluting Stent; remains on track for Japan launch in 1H16. 3Q15 adjusted operating margin of 23.1% exceeded the high end of the guidance range and represents improvement of 260 BP from last year.

$BSX {{ '2017-10-04T14:52:08+0000' | timeago}} • Announcement

$BSX appointed Desiree Ralls-Morrison as SVP, general counsel and corporate secretary. Ralls-Morrison will join $BSX on Nov. 30, 2017, as a member of the executive committee. Ralls-Morrison will succeed Timothy Pratt, EVP, general counsel and corporate secretary, who announced his intention to retire from the company in April 2017.

$BSX {{ '2017-10-02T20:46:11+0000' | timeago}} • Announcement

$BSX agreed to acquire privately-held Apama Medical Inc. for $175MM in cash upfront and a maximum of $125MM in contingent payments over 2018-2020 based on achievements of clinical and regulatory milestones. Closure is expected in 4Q17.  The deal is expected to be immaterial to adjusted EPS for 2017 and 2018 but more dilutive on a GAAP basis.

$BSX {{ '2017-09-19T15:14:32+0000' | timeago}} • Announcement

$BSX announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients study evaluating the performance of the HeartLogic Heart Failure Diagnostic to predict impending heart failure decompensation. The data demonstrate alert improves heart failure risk prediction.

$BSX {{ '2017-09-18T14:02:45+0000' | timeago}} • Announcement

$BSX announced results from a 3-year follow-up cohort in its Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty in Severe Persistent Asthma (PAS2) study. The patients with severe asthma show sustained clinical improvement and the data confirmed long-term effectiveness of Bronchial Thermoplasty.

$BSX {{ '2017-06-06T11:43:08+0000' | timeago}} • Announcement

$BSX received CE mark for the Vercise Gevia Deep Brain Stimulation (DBS) System, a rechargeable, magnetic resonance (MR) conditional device indicated for the treatment of movement disorder symptoms in patients with Parkinson's disease, dystonia and essential tremor.

$BSX {{ '2017-05-24T13:47:39+0000' | timeago}} • Announcement

$BSX announced positive results from the Post Approval Clinical Trial Evaluating Bronchial Thermoplasty (BT) in Severe Persistent Asthma (PAS2) study evaluating patients treated with the Alair System. The data demonstrate that BT reduces complications in adult patients with severe persistent asthma.

$BSX {{ '2017-05-16T11:09:11+0000' | timeago}} • Announcement

$BSX closed its acquisition of Symetis SA. On an adjusted basis, the transaction is expected to be immaterial in 2017, slightly accretive in 2018, and increasingly accretive thereafter. The transaction is expected to be less accretive (or slightly dilutive) on a GAAP basis, due to amortization expense and transaction and integration costs.

$BSX {{ '2017-05-16T11:08:03+0000' | timeago}} • Announcement

$BSX closed its acquisition of privately-held Swiss structural heart company Symetis SA. $BSX will immediately begin selling the Acurate TA and Acurate neo/TF valve systems in Europe and in other geographies outside of the U.S. Symetis will become part of $BSX Interventional Cardiology division.

$BSX {{ '2017-05-12T17:17:42+0000' | timeago}} • Announcement

$BSX announced positive European registry results for Watchman Left Atrial Appendage Closure (LAAC) Device. Data confirmed that the Watchman device had a high implant success rate and was effective in stroke reduction for patients with non-valvular atrial fibrillation (AF), including those patients deemed unsuitable for oral anticoagulation.

$BSX {{ '2017-05-12T17:12:37+0000' | timeago}} • Announcement

New analyses from $BSX sponsored PLATINUM Diversity study underscore the need for greater understanding of the clinical and nonclinical barriers that can adversely affect stent-related outcomes. PLATINUM Diversity is a first-of-its-kind study focusing exclusively on women and minorities with coronary artery disease.

$BSX {{ '2017-05-09T12:22:55+0000' | timeago}} • Announcement

$BSX has received US Food and Drug Administration approval for the Resonate family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems.

$BSX {{ '2017-04-27T12:49:55+0000' | timeago}} • Webcast

$BSX stated that the earnings and margin impact for the Lotus recall is that on the operating margin in 1Q17 it's 190 BP for the Lotus and Fuse charges. For the full year 2017, the company said it's 45 BP.

$BSX {{ '2017-04-27T11:19:18+0000' | timeago}} • Announcement

$BSX reported 13% spike in US revenues in 1Q17. In other regions, revenue grew 2% in Europe, 9% in AMEA and 12% in Emerging Markets.

$BSX {{ '2017-04-27T11:16:23+0000' | timeago}} • Announcement

$BSX estimates sales for 2Q17 in a range of $2.185-2.215Bil and earnings between $0.18 and $0.21 per share. Adjusted earnings were predicted to be between $0.30 and $0.32 per share.

$BSX {{ '2017-04-27T11:12:47+0000' | timeago}} • Announcement

$BSX now estimates revenue for FY17 in a range of $8.8-8.9Bil (compared to prior guidance of $8.675-8.875Bil). Net income is expected between $0.81 and $0.86 per share (compared to prior guidance of $0.86-0.91 per share). Adjusted earnings outlook was reaffirmed at a range of $1.22-1.26 per share.

$BSX {{ '2017-04-27T11:08:18+0000' | timeago}} • Announcement

$BSX's sales in 1Q17 rose to $2.16Bil, helped by revenue growth in all segments. In a YoY basis, MedSurg revenue jumped 15%; Cardiovascular grew 8%; and Rhythm Management increased 7%.

$BSX {{ '2017-04-27T11:01:45+0000' | timeago}} • Announcement

Medical device maker $BSX reported 10% growth in revenue in 1Q17, which helped it post higher earnings. Net earnings were $290MM or $0.21 per share, compared to $202 million or $0.15 per share a year ago. On an adjusted basis, net earnings grew to $0.29 per share.

$BSX {{ '2017-04-19T21:19:50+0000' | timeago}} • Announcement

$BSX's total assets were $14.9Bil at March 31, 2017 compared with $13.9Bil at March 31, 2016. Total deposits were $12Bil at March 31, 2017 compared with $11.5Bil at March 31, 2016. During 1Q17, the company repurchased 1,613,691 shares of its outstanding common stock at a weighted average price of $30.62 per share.

$BSX {{ '2017-04-19T21:15:05+0000' | timeago}} • Announcement

Banking firm $BSX reported a nearly 70% increase in its 1Q17 profit. Net income surged to $38.1MM or $0.41 per share from $22.5MM or $0.24 per share in the prior year quarter. Results included a positive MSR valuation adjustment of $0.9MM for 1Q17 compared with a negative MSR valuation adjustment of $8MM a year ago.

$BSX {{ '2017-03-30T13:05:53+0000' | timeago}} • Announcement

$BSX will acquire Symetis SA for $435MM in up-front cash to strengthen its global positioning in the treatment of structural heart disease.  On an adjusted basis, the transaction is expected to be immaterial in 2017, slightly accretive in 2018, and increasingly accretive thereafter.

Recent Transcripts

UNH (UnitedHealth Group Incorporated)
Tuesday, October 17 2017 - 12:45pm
CMD (Cantel Medical Corp.)
Thursday, September 28 2017 - 3:00pm
PTN (Palatin Technologies Inc.)
Monday, September 25 2017 - 3:00pm
MDT (Medtronic plc)
Tuesday, August 22 2017 - 12:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, August 9 2017 - 9:00pm
INFU (InfuSystem Holdings, Inc.)
Wednesday, August 9 2017 - 8:30pm
LIVN (LivaNova PLC)
Wednesday, August 9 2017 - 1:00pm
STE (Steris Plc)
Tuesday, August 8 2017 - 2:00pm
OFIX (Orthofix International N.V.)
Monday, August 7 2017 - 8:30pm
HAE (Haemonetics Corporation)
Monday, August 7 2017 - 12:00pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
CYTK (Cytokinetics, Incorporated)
Wednesday, August 2 2017 - 8:30pm
MASI (Masimo Corporation)
Wednesday, August 2 2017 - 8:30pm
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
PCRX (Pacira Pharmaceuticals, Inc.)
Wednesday, August 2 2017 - 12:30pm
RMD (ResMed Inc.)
Tuesday, August 1 2017 - 8:30pm
LXRX (Lexicon Pharmaceuticals, Inc.)
Tuesday, August 1 2017 - 12:00pm
HRC (Hill-Rom Holdings, Inc.)
Friday, July 28 2017 - 12:30pm
PTX (Pernix Therapeutics Holdings, Inc.)
Thursday, July 27 2017 - 8:30pm
NUVA (NuVasive, Inc.)
Thursday, July 27 2017 - 8:30pm

AlphaGraphics you may like